|
IMS
Pipeline:
Being the innovator of the
prefilled disposable syringe since 1970, IMS has
provided the medical community a variety of
medications, including critical care products, pain
management products, PCA products and local
anesthetic products.
R&D at IMS has experienced
tremendous growth since it was acquired by Amphastar
Pharmaceuticals, Inc. in October of 1998. Many
drugs have been developed and have received
FDA approval.
Furthermore, IMS shares and
supports Amphastar’s focus on developing:
|
Ø |
Difficult to produce
products, such as emulsions and suspensions. |
|
Ø |
Generic products with
a significant market, but with no available
API. |
|
Ø |
New products with a
unique marketing niche. |
|
Ø |
New delivery systems
for well established products. |
IMS is committed to developing and growing its
pipeline as it continues to grow and diversify as a
company.
|
